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1 The role of CFTR genetic testing in diagnosis of cystic ﬁbrosis
S. Fustik1, T. Jakovska1. 1University Pediatric Clinic, Center for Cystic Fibrosis,
Skopje, Macedonia, the Former Yugoslav Republic of
The large number of different mutations in CFTR gene combined with marked
variation in their distribution and frequency make the genetic diagnosis of CF
rather difﬁcult. The aim of the study was to estimate the detection rate of CFTR
mutations in our patients according to the results from the genetic testing performed
at Research Center for Genetic Engineering and Biotechnology (Skopje).
Methods: CFTR genotype results from 140 patients who had conﬁrmed clinical
diagnosis of CF were analyzed. The mainly used molecular analysis methods
included: PAGE of PCR-ampliﬁed fragments of DNA for the detection of F508del;
Inno-LiPA CFTR17 and Inno-LiPA CFTR19 panels for identiﬁcation of 36 CFTR
mutations; and DGGE mutations screening, followed by sequencing of samples
showing an abnormal pattern.
Results: Mutation detection rate in our group of patients was 83%. The frequency
of the most common mutations was: F508del (69.2%), G542X (6.1%), N1303K
(2.9%), 621+1G>T (1.1%) and CFTRdel2,1(21kb) (1.1%). Six DNA samples from
CF patients in which one or no CFTR mutations have been identiﬁed were sent
for analysis in Laboratoire de Ge´ne´tique Mole´culaire, Brest (France). With more
extensive screening/sequencing protocols and methods for identiﬁcation of large
rearrangements, all unknown mutations were identiﬁed.
Conclusion: The diagnosis of CF remains clinical. Indetermination of CFTR
mutations arouse doubts in families about the accuracy of diagnosis. Because of
genetic heterogeneity of CF in our region, there is a need for additional methods
for CFTR gene analysis to maximize mutant allele detection rate, which will have
positive implications for the genetic counseling of families.
2 The syndrome of exocrine pancreatic insufﬁciency − cystic ﬁbrosis
or other disease?
A. Sobczyn´ska-Tomaszewska1,2, K. Czerska1,2, A. Szpecht-Potocka1,
D. Popielarz1, K. Wertheim-Tysarowska2, K. Niepoko´j2, B. Oralewska3,
J. Bal2. 1Health Care Center Genomed, Warsaw, Poland; 2Institute of Mother and
Child, Department of Medical Genetics, Warsaw, Poland; 3Children’s Memorial
Health Institute, Department of Gastroenterology, Warsaw, Poland
The Shwachman-Diamond syndrome (SDS), is rare disease (1/100 000 live births)
caused by compound heterozygous/homozygous mutations in the SBDS gene.
SDS is characterized primarily by exocrine pancreatic insufﬁciency, hematologic
abnormalities, including increased risk of malignant transformation, and skeletal
abnormalities. The pancreatic insufﬁciency which is observed in this syndrome, may
suggests clinical observation for cystic ﬁbrosis and may caused in delay in diagnosis
of patient. A Polish girl with abnormal result of IRT during newborn screening
programme for cystic ﬁbrosis was directed for clinical and genetic evaluation for
cystic ﬁbrosis and CFTR gene analysis. Sequencing of whole coding region of the
CFTR gene together with identiﬁcation of frequent for Polish population mutations:
dele2,3(21kb) and 3849+10kbC>T were performed. No pathogenic CFTR variants
were identiﬁed. Only the I148T variant, without clinical consequence according
to CF recommedation was identiﬁed. Because patient presented chronic pancreatic
and liver disease, anemia, decrease concentration of stool elastase, hipertransam-
inasemia, borderline/normal sweat test results and short stature were observed,
clinical observation and genetic analysis for Shwachman-Diamond syndrome was
suggested as a next diagnostic stage. Analysis of coding region of the SBDS gene
were performed. Two known mutations: c.258+2T and p.C119Y, each in one SBDS
allele were identiﬁed. Biparental inheritance of identiﬁed mutations was conﬁrmed.
In conclusion, because of the similarity of some symptoms in cases of atypical
abdominal form of the CF, the SDS should be taken into account during diagnosis
process.
3 CFTR gene direct sequencing versus scanning techniques.
Improving the sensitivity to identify CF mutations
D. Trujillano1, M.D. Ramos2, A. Vazquez2, X. Estivill1, J. Manzanares3,
T. Casals2,4. 1Centre for Genomic Regulation, Genes and Disease Program,
Barcelona, Spain; 2IDIBELL, Center for Molecular Genetic Diagnosis, Barcelona,
Spain; 3Hospital 12 de Octubre, Cystic Fibrosis Unit, Madrid, Spain; 4IDIBELL,
Human Molecular Genetics Group, Barcelona, Spain
From the CFTR gene cloning, the scanning techniques (SSCP/HD, DGGE, DHPLC,
HRM, MLPA) have been applied to detect CF mutations. Using different scanning
procedures, we have identiﬁed over 250 CFTR mutations accounting for 97% of CF
alleles. To evaluate this sensitivity, we have assessed the CFTR direct sequencing
analysis in front of the scanning strategy. Ten samples with partial/total unknown
genotype have been selected among our patients. Three out 20 alleles were already
known (p.Phe508del, p.Cys592Tyr and c.1209G>A). Sequencing analysis showed
one homozygous patient for the p.Ser549Arg mutation, one patient heterozygous
for p.Met1101Lys and two patients bearing the p.Gly673X. Revision of our previous
analysis has evidenced: (1) primers used in the early 1990s were unable to detect
the p.Met1101Lys; (2) absence of heteroduplex bands in the two other mutations.
It is well known the limitation of these techniques to detect homozygous changes;
however, we do not ﬁnd an explanation for the p.Gly673X mutation localized in the
ﬁrst half of exon 14. Usually, this large exon (723 nt) is analyzed in two overlapping
fragments and other 23 different mutations have been identiﬁed in our series.
Once again, we have taken advantage of the microsatellite haplotype (IVS8CA-
IVS17bTA) associated to this mutation. Available CF samples still uncharacterized
showing the 16−34 haplotype (n = 6) were sequenced speciﬁcally. The p.Gly673X
mutation was identiﬁed in another patient. Our results evidence a higher sensitivity
using sequencing analysis, a powerful tool now more affordable with the new
equipments.
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4 Advances in the use of high resolution melting analysis for prenatal
diagnosis and evaluation of p.Phe508del unlabelled probe
M. Poulou1, A. Destouni1,2, E. Kanavakis1,2, M. Tzetis1. 1University of Athens,
Medical Genetics, Athens, Greece; 2Research Institute for the Study of Genetic
and Malignant Disorders in Childhood, Athens, Greece
High Resolution Melting Analysis (HRM) is an inexpensive, fast and robust method
for detecting sequence changes in genomic DNA. The method consists of PCR
ampliﬁcation of the fragment in question, in presence of a dsDNA intercalation
ﬂuorescent dye. Following PCR the samples are melted revealing a unique melting
proﬁle according to their sequence composition. In our laboratory we evaluated the
method using Idaho’s Technology LightScanner® system and are currently using it
as a routine method for screening. The primers used are from Montgomery et al.
(Clin. Chem. 2007). All positive ﬁndings are conﬁrmed by subsequent by-directional
sequencing.
Factors which limit HRM’s scanning and genotyping efﬁciency include primer and
probe design as well as DNA quality and quantity. These factors hinder the broad
application of HRM in samples coming from populations with genetic variability
and in samples from various sources (already extracted DNA samples sent from
different laboratories, old DNA samples or DNA from amniotic cells and/or CVS).
In order to overcome the limitation arising from DNA quality and quantity we
have developed a protocol which allows us to analyze consistently and with high
speciﬁcity, samples from variable sources extracted in different ways.
In addition we focus on a speciﬁc drawback on the detection of the p.Phe508del
mutation using the unlabelled probe as described in the paper by Mont-
gomery et al. which could lead to misdiagnosis of carriers with the genotype
p.[Leu467Phe;Met470Val;Phe508del] + [=] due to allele dropout caused by primer
positioning.
